ORKA: ORKA-001 reproduced high week 16 clearance rates; 600 mg is the planned phase III dose

What happened

ORKA-001 achieved 61% PASI 100 and 86% PASI 90 at week 16 with the 600 mg dose, consistent with the EVERLAST-A study; pooled across both studies, PASI 100 was about 63%. The 600 mg regimen is planned for phase III in the first half of 2027, pending regulatory discussions.

Confirmed

Global impact / market context

Reproducing week 16 skin-clearance results in a second study reduces the risk that the earlier EVERLAST-A outcome was a fluke. That consistency supports the planned phase III program and may strengthen the company's position in regulatory talks over the 600 mg dose.

Analyst inference

For investors, the key read is that the next major value step is phase III planning and regulatory feedback, not new early data. Success would require large capital spending over years before any product revenue, so the cash available to fund those trials matters.

Analyst inference

What to watch

1. The company expects the 600 mg regimen to enter phase III in the first half of 2027, but that timing depends on regulatory discussions, which means talks with regulators about trial design. Confirmed
2. Watch whether a phase III design using 600 mg repeats the about 63% pooled PASI 100 clearance rate, which is the share of patients achieving clear or almost clear skin. Analyst inference
3. Watch for disclosure of planned capital spending and cash available for phase III, because long, large trials raise costs before any revenue arrives and can affect investor positioning. Proposed

Evidence

• Original source link unavailable